Tyrosine kinase inhibitors after progression on atezolizumab-bevacizumab in advanced hepatocellular carcinoma: A systematic review and meta-analysis

doi:10.4254/wjh.121656

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 6

This Article

(20)

(0)

(462)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Jun 27, 2026; 18(6): 121656
Published online Jun 27, 2026. doi: 10.4254/wjh.121656

Full Size Figure Download Figure

Figure 5 Forest plots of clinical response outcomes according to modified Response Evaluation Criteria in Solid Tumors (modified Response Evaluation Criteria in Solid Tumors). A: Complete response; B: Partial response; C: Stable disease; D: Progressive disease; E: Objective response rate; F: Disease control rate; G: Not evaluable. REML: Restricted maximum likelihood; CI: Confidence interval.

Citation: Blanco Montecino R, Rodriguez NG, Coreas N, Mendoza-Quispe D, Kilani Y, Kamal SAF, Qureshi K, Richart JM. Tyrosine kinase inhibitors after progression on atezolizumab-bevacizumab in advanced hepatocellular carcinoma: A systematic review and meta-analysis. World J Hepatol 2026; 18(6): 121656
URL: https://www.wjgnet.com/1948-5182/full/v18/i6/121656.htm
DOI: https://dx.doi.org/10.4254/wjh.121656

Blanco Montecino R, Rodriguez NG, Coreas N, Mendoza-Quispe D, Kilani Y, Kamal SAF, Qureshi K, Richart JM. Tyrosine kinase inhibitors after progression on atezolizumab-bevacizumab in advanced hepatocellular carcinoma: A systematic review and meta-analysis. World J Hepatol 2026; 18(6): 121656 [DOI: 10.4254/wjh.121656]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.